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AbstrAct
To explore the relationship between innate immunity and hepatitis C Virus 
(HCV) in determining the risk of cirrhosis (CIR), hepatocellular carcinoma (HCC), 
mixed cryoglobulinemia syndrome (MCS) and non-Hodgkin lymphoma (NHL), we 
investigated the impact of the toll-like receptor-2 (TLR2) and interleukin-28B (IL28B) 
genetic variants. TLR2 -174 del variant was associated with TLR2 expression and with 
specific downstream molecules that drive the expression of different interleukins; 
rs12979860 Il28B was important in response to interferon-treatment and in 
spontaneous clearance of HCV. The risk for liver and lymphoproliferative diseases in 
HCV progression was clarified by stratifying 862 HCV-positive patients into groups 
based on liver (CIR, HCC) and lymphoproliferative HCV-related diseases (MCS, NHL) 
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IntroductIon
Chronic HCV-infection (CHC) may induce 
cirrhosis and hepatocellular carcinoma (HCC), but 
also B-cell dysregulations such as autoimmune type II 
mixed cryoglobulinemia syndrome (MCS) and B-cell 
non-Hodgkin lymphoma (NHL) [1-3]. The mechanisms 
whereby HCV establishes hepatic or lymphoproliferative 
diseases are still poorly understood. 
Innate immune response relies on recognition of 
pathogen-associated molecular patterns (PAMP) through 
pattern recognition receptors (PRRs) that include the toll-
like receptors (TLRs). TLR2, TLR3, TLR7 and TLR9 
have a crucial role in host defense against HCV infection 
and HCV liver diseases [4-7]. Like other TLRs (TLR1, 
TLR4, TLR5, TLR6 and TLR10), TLR2 is predominantly 
expressed on the cell surface to sense extracellular 
PAMPs. In contrast, TLR3, TLR7, TLR8 and TLR9 are 
located in intracellular compartments and recognize 
viral nucleotides. TLR2 has been associated with 
hepatocarcinogenesis and is known to be triggered by the 
core-protein of the HCV nucleocapsid [8-12]. Intriguingly, 
specific TLR polymorphisms, mainly the TLR2 -196 to 
-174 ins/del, influence the extent of TLR2 expression and 
have been associated with more advanced liver diseases 
[13, 14]. TLRs signal through specific downstream 
molecules that finally activate transcription factors driving 
the expression of different cytokines including interferons 
[15, 16]. 
Inappropriate production of interferons has been 
associated to various HCV-related processes that may 
be the prelude to malignant complications [17, 18]. 
Interferon-lamba (IFNλ) is a family of four genes: IFNλ1 
(IL29), IFNλ2 (Il28A), IFNλ3 (IL28B) and IFNλ4 (a 
frameshift variant of IL28B) [19]. They target the IL28Rα 
and IL10Rb receptors resulting in the activation of Janus 
kinase/signal transducers and activators of transcription 
(JAK/STAT) signaling with expression of interferon-
stimulated genes (ISGs) and induction of an antiviral state. 
However, unlike type I IFN receptor, which was expressed 
on virtually all cell types, IL28Rα was only expressed on 
specific tissues such as epithelia [20]. A single nucleotide 
polymorphism (SNP) in the promoter region of the IL28B 
gene, the rs12979860, was originally associated with 
spontaneous and treatment-induced clearance of genotype 
1 HCV infection [2, 17, 21-26] . 
We hypothesized that, if TLR2 and IL28B were 
functionally interconnected in HCV diseases-specific 
networks, both TLR2 and IL28B polymorphisms could 
have a critical role in the pathogenesis of HCV-related 
disorders. 
To test this hypothesis, we investigated TLR2 -196 
to -174 ins/del and rs12979860 IL28B polymorphisms in 
HCV-related liver and lymphoproliferative diseases in an 
Italian population.
results
Patients characteristics and group distribution
Patient characteristics and group distribution were 
shown in Table 1. Gender and HCV genotypes were 
found differentially distributed among HCV-related 
disease groups. Male gender was preferentially found 
associated with liver diseases (CIR and HCC; 67 to 71%), 
while female gender was more frequent in patients with 
lymphoproliferative disorders (MCS and NHL; 63 and 
61%). HCV genotype 1 was the most frequent genotype 
found in our population (53 to 82%). No association 
between HCV genotypes and HCV viral load was 
observed.
Genotype frequencies of tlr2 ins/del 
polymorphism in chronic HcV infection, HcV-
related liver and lymphoproliferative diseases
Figure 1 shows the genotype frequencies of TLR2 
ins/del (-196 to -174) polymorphism in patients with HCV, 
HCV-related diseases and blood donors (BD). Distribution 
of BD TLR2 ins/del genotype frequencies in our case 
series was similar to that reported in the literature [13]. 
Carriers of wild-type TLR2 (ins/ins) genotype represented 
71.6 % of all HCV-positive patients, with a frequency of 
70% to 77% in the different HCV-related diseases, and 
75% in BD (Figure 1). Data indicated a slight association 
between TLR2-del allelic variant with HCV infection, but 
the difference was not significant when polymorphism 
frequencies of all HCV-positive patients were compared 
to those of BD (dominant TLR2 ins/ins vs TLR2 ins/del 
+ TLR2 del/del, OR = 1.20, Table 2). However, patients 
and compared with chronic HCV (CHC) infection. Analysis of TLR2-IL28B haplotypes 
showed an association of wild type haplotype with the lymphoproliferative diseases 
(OR 1.77, p = 0.029) and a slight increase in HCV viral load (HR 1.38, p = 0.054). 
Wild type haplotype (TLR2 ins/ins- IL28B C/C) was also found associated with older 
age in patients with an hepatic diseases (in CIR and in HCC p = 0.038 and p = 0.020, 
respectively) supporting an effect of innate immunity in the liver disease progression. 
TLR2 and IL28B polymorphisms in combination showed a role in the control of HCV 
viral load and different HCV disease progression.
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Figure 1: distribution of tlr2 and Il28b genotypes among HcV-positive population groups. TLR2 and IL28B genotypes 
frequencies and relative number of cases in patients with chronic HCV infection (CHC), with HCV-related cirrhosis (CIR), with HCV-
related hepatocellular carcinoma (HCC), with HCV-related mixed cryoglobulinemic syndrome (MCS), with HCV-related non Hodgkin 
lymphoma (NHL) and in blood donors (BD). 
Figure 2: one-way Anova test for tlr2 and Il28b variant alleles and for tlr2 and Il28b genotypes. Data were 
represented as mean with Standard Error of measurement (±SEM). Only statistically significant comparisons were illustrated. The del/del 
TLR2 genotype was significantly higher in patients with HCV-related hepatocellular carcinoma (HCC) compared to all the other groups 
(p = 0.004) (**). Patients with HCV-related liver damage showed a higher IL28B T allele mean value than blood donors (BD) (p = 0.001, 
CHC reference group) and patients with lymphoproliferative diseases (MSC and NHL, p = 0.012, CHC reference group).
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carrying TLR2 del/del genotype showed an increased 
risk for HCC compared with all other groups of patients 
and BDs by using pair wise comparison test (one-way 
analysis of variance HCC vs NHL p = 0.004; Figure 
2). In particular, a positive trend between TLR2 del/
del genotype and an increasing risk for HCC (i.e CHC: 
4.3%; CIR: 4.9%; HCC: 10.3%) was found; by contrast, 
the TLR2 del/del prevalence in NHL patients (0.9%) 
was similar to that found in BDs (1.3%). Thus, findings 
indicated that TLR2 del/del genotype condition correlate 
with primary liver cancer rather than HCV-positive 
malignant lymphoproliferation. No additional significant 
differences was observed for TLR2 ins/del genotype or 
allele frequencies. 
Genotype frequencies of rs12979860 Il28b 
polymorphism in chronic HcV infection, HcV-
related liver and lymphoproliferative diseases
The results of IL28B genotyping in patients with 
HCV-related diseases and BDs were shown in Figure 1. 
Distribution of rs12979860 genotype frequencies found in 
our series was similar to those reported in the literature 
[17, 21, 22]. Results of previous studies where IL28B C/C 
genotype enhanced the spontaneous resolution of HCV 
infection indirectly support a possible role for the IL28B 
C allele in the control of HCV infection. In keeping with 
these observations, we found a negative trend for CC 
genotype frequencies, balanced by an increased trend in 
TT genotype, in HCV-positive patients compared with 
BDs (IL28B C/C dominant polymorphism vs IL28B C/
T+ IL28B T/T: OR 0.46 p = 0.025, Table 2). One-way 
test confirmed the significant positive trend for T allele 
in patients with chronic HCV-infection, which was 
more evident in patients with liver damage instead of a 
lymphoproliferative disorder (Figure 2). Thus, the analysis 
indicated a T allele gradient able to discriminate a chronic 
status more prone to evolve into liver injury from a 
condition more likely developing a lymphoproliferative 
dysfunction (p = 0.001, Figure 2).The frequency of IL28B 
T allele in CHC, CIR , HCC was 43.7%, in MCS, NHL 
was 35.1% in BDs was 27.2%. 
tlr2-Il28b haplotypes in chronic 
HcV infection, HcV-related liver and 
lymphoproliferative diseases
No linkage disequilibrium between TLR2 and 
IL28B polymorphisms was found as the test for correlation 
resulted not significant (862 data pairs tested; coefficient 
Table 1: Main clinical and laboratory findings of HCV chronically infected patients according to liver-related damage 
and extrahepatic conditions.
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table 2: Genotype associations with HcV infection
dominant recessive Additive 1 Additive 2
Gene 
polymorphism P-value or (95% cI) P-value or (95% cI) P-value
or (95% 
cI) P-value or (95% cI)
TLR2
 ( ins→del)
IL28B
rs12979860 
(C→T)
 
0.521
 
0.025
1.20 (0.69-
2.06) 
0.46 (0.28-
0.76)
 
0.168 
 
0.260
4.09 (0.47 -1.41)
1.99 (0.60-6.58)
 
0.325
 
0.082
  
0.76 (0.43-
1.32)
1.84 (0.92-
3.66)
 
0.167 
 
0.075
  
4.118 (0.55-30.61)
3.05 (0.89-10.41)
HCV-positive patients (n= 862) were compared with respect to the reference category of blood donors (n=77). OR, odds 
ratio; CI, confidential interval. WT: wild type is the most frequent polymorphism found in the general population. For the 
TLR2 SNP indicated like  ins and del variant; a single band at 286 bp was judged as WT, while heterozygous type revealed 
two bands of 286 bp and 264 bp (del variant).  Genotypes of each polymorphism were assessed according to dominant (1 
wild-type homozygote; 0 heterozygote and variant homozygote), recessive (0 wild-type homozygote and heterozygote; 1 
variant homozygote) and additive genetic models. Additive models comprised additive 1 (1 heterozygotes versus 0 wild-
type homozygotes) and additive 2 (1 variant homozygotes versus 0 wild-type homozygotes) models. Dominant indicated 
homzygous WT alleles, which was for the TLR2 the ins/ins genotype and for the IL28B the C/C genotype.
table 3: Frequencies of tlr2 /Il-28b haplotypes based on HcV-related diseases and blood donors (bd). 
Usually, TLR2 SNP has indicated like  -196 to -174 del. A single band at 286 bp was judged as wild type, and a single 264 bp 
band was judged as homozygous type, while heterozygous type revealed two bands of 286 bp and 264 bp.
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of correlation 0.03). The TLR2-IL28B polymorphisms 
formed several haplotypes, whose frequency was reported 
on Table 3. The distribution analysis of haplotypes 
confirmed that specific haplotypes discriminated between 
HCV-positive patients more likely evolving towards 
liver damage and those instead evolving towards a 
lymphoproliferative disorder. Indeed, a significant lack 
of the TLR2-ins/ins IL28B-C/C haplotype was not only 
associated with a chronic HCV status (p = 0.007, OR 2.94, 
Table 4) but closely correlated with a liver damage, rather 
than a lymphoproliferative-disease progression (p = ns, 
OR 1.05; p = 0.029, OR 1.77, respectively, Table 4). 
relationship between HcV viral load and tlr2- 
Il28b haplotype
HCV viral load was assessed in serum samples 
for 197 patients at diagnosis. A higher HCV viral load 
was mainly associated with the presence of IL28B C/C 
rather than that of IL28B T/T genotype (IL28B additive 
2, p = 0.005, HR 1.68, 95% CI 1.02-2.75, Table 5) and 
TLR2 ins/del genotype than homozygous (TLR2 additive 
1, p = 0.026, HR 1.30, 95%CI 0.96-1.73). Multivariate 
regression analysis indicated that IL28B T/T recessive 
genotype was independent of HCV genotype, age, patient 
gender and TLR2 variables and it was associated with a 
lower HCV viral load (p = 0.044, exp 1.52 95% CI 1.01-
2.27). 
relationship between liver disease progression 
and tlr2- Il28b haplotype
Given the potential role of host immunity in the 
control of HCV-infected tumor cells and the potential 
of age-related influences on tumor progression, we also 
looked for a liver disease age-related trend and TLR2-
IL28B haplotype. Continuous age variable was analyzed 
between liver and lymphoproliferative groups with respect 
to the dominant wild-type TLR2- IL28B haplotype, 
and a significant association was found with BDs and 
patients with a lymphoproliferative disease. A significant 
difference was found in the mean age between patients 
having a dominant haplotype and a liver disease compared 
to those having a different haplotype (CIR patients: 68.9 
vs 62.0 mean age, p = 0.038; HCC: 72.4 vs 67.7 mean age, 
p = 0.02; Figure 3).
dIscussIon
Immunogenetic profile may play an important 
role in determining the progression of chronic HCV 
infections to different diseases [1-3, 5, 27]. We confirmed 
the role of rs12979860 IL28B-C allele-carrier as a 
protective factor for CHC [2, 17, 21-26]. In addition, 
we highlighted that the IL28B C/C genotype correlates 
with lymphoproliferative disease when associated with 
a TLR2-ins allele in homozygosity (Table 4). On the 
contrary, homozygous TLR2-del allele (TLR2-del/
del) exhibits a significantly higher threshold for HCC 
development (Figure 2). Overall, the present results were 
consistent with an interlocked role between TLR2 and 
IL28B (IFN-λ3) gene variants in directing HCV-related 
table 4: TLR2-IL28B  haplotype association with blood donors and HcV-positive patients affected by liver (cirrhosis 
and hepatocellular carcinoma) or lymphoproliferative diseases (type II cryoglobulinemia and non-Hodgkin’s 
lymphoma) compared with respect to chronic HcV infection (cHc).
dominant (Ins/Ins-
C/C)
recessive (del/del-
T/T)
Additive 1 (hetero vs 
homoz)
Additive 2 (Ins/Ins-
C/C vs  del/del-T/T )
Individual status P-value or (95% cI) P-value
or (95% 
cI) P-value or (95% cI) P-value or (95% cI)
Blood donors
Hepatic disease
Lymphoproliferative 
disease
0.007
0.857 
0.029
2.94 (1.34-
6.47)
1.05 ( 0.62-
1.78) 
1.77 (1.06-
2.95)
0.92
0.633
0.284
0.85 (0.033-
21.27)
0.51 (0.032 
-8.18)
0.17 (0.01-
4.30)
0.030
0.190 
0.056
  
0.44 (0.21-
0.92)
0.75 (0.49-
1.15)
0.66 (0.43-
1.01)
0.718
0.562  
0.200
  
0.55 (0.021-
14.3)
0.47 (0.03-
7.17)
0.12 (0.01-
3.05)
Reference category: CHC, chronic HCV-positive patients
Abbreviations: OR, odds ratio; CI, confidential interval.
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diseases progression. Indeed, it has been shown that TLR2 
was able to activate transcription factors that drive the 
expression of antiviral genes and different cytokines, such 
as interferons [15, 16]. Several studies have indicated a 
relation among rs12979860 IL28B gene, spontaneous 
clearance of HCV and therapeutic outcomes of genotype 
1 HCV-positive patients treated with IFN-based therapies 
[2, 21-26]. In 2013 a new interferon, the IFN-λ4, was 
identified. The rs368234815 polymorphism originating 
the IFN-λ4 by creation of a new open reading frame [19, 
28] was found in strong linkage disequilibrium with the 
rs12979860 IL28B so much it has been described as the 
functional variant of the rs12979860 IL28B [19, 29]. Thus, 
spontaneous and treatment-induced clearance of HCV 
resulted equally dependent on rs12979860 or rs368234815 
polymorphisms and combined assessment of these gene 
polymorphisms did not increase the predictive value of 
IL28B polymorphisms in HCV-positive patients [19, 29]. 
More recently, it was found that Y93H, a variant present 
in the NS5A region of HCV, was significantly associated 
with the beneficial rs12979860 polymorphism confirming 
the functional role of IFN-λ4 SNP in HCV-infection [30]. 
The haplotype data presented herein (Table 4) provided 
evidence supporting a role for IL28B in relation with 
TLR2 polymorphism to predict progression to different 
HCV-related diseases. Recent functional studies have 
demonstrated that IL28B T/T genotype was associated 
with a higher production of IFN-λ3 and higher ISGs gene 
expression in HCV-infected liver tissue, and that this 
higher baseline level of ISGs expression may contribute 
to an interferon-refractory state in the liver [31]. Thus, it 
has been hypothesized that the high baseline ISG levels 
found in IL28B T/T carriers can lead to a poor response to 
INF-based therapy due to an exhaustion of the interferon-
response pathway [32]. In keeping with this model, a 
satisfactory treatment response could be associated with 
a IL28 C/C genotype, a lower levels of ISGs expression 
and thus a higher levels of circulating HCV RNA [33]. 
Our findings about higher viral load in patients having 
IL28B C/C genotype may support this hypothesis. A 
higher viral load was associated with HCV genotype 1, 
but difference among genotypes did not reach a statistical 
significance in our series. The observed broader frequency 
of IL28-T allele in patients with hepatic rather than 
lymphoproliferative disorders can be explained by the fact 
that the IL28-R/IL-10R receptor complex was expressed 
only in restricted cell types, like hepatocytes, epithelial 
cells and plasmacytoid dendritic cells [34]. Considering 
that HCV was primarily hepatotropic, it is reasonable to 
assume that IL28B-T allele could likely contribute to an 
IFN-refractory state mostly in the liver. In this regard, 
it has been observed that the expression levels of ISGs 
were differentially regulated in the liver and peripheral 
blood [35, 36]. In addition, higher level of HCV infection 
in hepatocytes induced higher level of endoplasmatic 
reticulum stress and caused HCC carcinogenesis [37]. 
In this scenario, TLR2-del variant, which was related to 
a diminished expression of TLR2 level, and secretion 
table 5: TLR2 and IL28B  genotype and TLR2-IL28B haplotype association with HcV viral load
Abbreviations: HR. hazard ratio; CI. confidential interval. Hazard ratio; CI. confidential interval. Hazard ratio; CI. confidential 
interval. WT: wild type is the most frequent polymorphism found in the general population. For the TLR2 SNP indicated 
like  ins and del variant; a single band at 286 bp was judged as WT, while heterozygous type revealed two bands of 286 bp 
and 264 bp (del variant).  Genotypes of each polymorphism were assessed according to dominant (1 wild-type homozygote; 
0 heterozygote and variant homozygote), recessive (0 wild-type homozygote and heterozygote; 1 variant homozygote) and 
additive genetic models. Additive models comprised additive 1 (1 heterozygotes versus 0 wild-type homozygotes) and additive 
2 (1 variant homozygotes versus 0 wild-type homozygotes) models. Dominant indicated homozygous WT alleles, which 
was for the TLR2 the ins/ins genotype and for the IL28B the C/C genotype. Multivariate stepwise tested for age, sex, HCV 
genotype, TLR2 and IL28B variables.
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of immunosuppressive cytokines, increased the hepatic 
inflammatory microenvironment and the risk of HCC 
development [8, 13, 38]. Consistently, TLR2 knock-
down (TLR2 -/-) mice showed enhanced inflammation, 
hepatic lesions and HCC progression after carcinogenic 
diethylnitrosamine exposure [9, 39]. Moreover, the TLR2 
del/del condition resulted more frequently detected in our 
HCC patients than in other HCV-related diseases (Figure 
2). Data were in agreement with those observed in the 
HCV German population with an increased risk of HCC 
associated with the TLR2-del variant [13]. On the other 
hand, our multivariate analysis showed that IL28B C/C 
genotype was associated with a higher viral load (Table 5) 
and that the dominant wild-type haplotype (TLR2 ins/ins-
IL28B C/C) correlated with lymphoproliferative diseases 
but also with BDs (Table 4). Likewise, previous studies 
have shown that HCV-core protein triggering TLR2 leaded 
to an increased in B-cell proliferation in vitro [18]. Thus, 
considering that HCV is also a lymphotropic virus, our 
haplotype analysis pointed out that in the presence of 
a HCV chronic persistence, the TLR2 ins/ins-IL28B-
C/C arrangement could increase the susceptibility to 
lymphoproliferative complications, including mixed 
cryoglobulinemia and B-cell NHL (p = 0.029, OR 1.77, 
Table 4). In addition, the TLR2 ins/ins-IL28B-C/C 
haplotype not only showed a potential protective effect 
against HCV infection but also an association with older 
patients having a liver diseases (CIR and HCC, Figure 3), 
thus, suggesting that the protective effect associated with 
this haplotype decreased with age. 
In conclusion, our study emphasizes that both TLR2 
and IL28B polymorphisms may have a role in directing 
HCV-progression towards hepatic or lymphoproliferative 
diseases. Thus, the analysis of our HCV-positive 
population stratified by the two immunological variables 
indicated a potential protective effect of the IL28B-C 
Figure 3: Boxplot describing the relationship of TLR2-IL28B haplotype with the patient disease stratified by the 
median age at diagnosis. Boxes range from the 25th to the 75th percentile with a horizontal black line at the median and vertical lines 
extending to the 10th and 90th percentiles. The wild type TLR2-IL28B haplotype showed an association with the older patients having a 
liver disease (patients with HCV-related cirrhosis (CIR)(*)(p = 0.038) and patients with HCV-related hepatocellular carcinoma (HCC)(*)(p 
= 0.02). We found no difference in the median age at diagnosis in patients with lymphoproliferative diseases.
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allele in homozygosity (IL28B-C/C) towards chronic 
infection and liver diseases, and that the simultaneous 
presence of at least one TLR2-del allele abolished this 
effect. In accordance with this result, the TLR2-del/
del state appeared closely linked with HCC condition. 
Conversely, the dominant wild-type haplotype (TLR2 
ins/ins-IL28B C/C) associated with a better spontaneous 
resolution of the infection was also found more frequently 
in both BDs as well as in HCV-related lymphoproliferative 
disorders compared to CHC, suggesting that, in patients 
with a lymphoproliferative disease, additional factors 
may be involved that obstacle the elimination of the virus. 
Therefore, our findings shed new light on the mechanisms 
underlying the persistence of HCV infection and HCV-
related disease progression. A deeper understanding of 
these processes may lead to development of strategies 
based on the combination of conventional therapies with 
immune-mediated strategies for the treatment of HCV-
related diseases.
MAterIAls And MetHods
study samples
 We considered 862 patients with chronic HCV-
infection and 77 healthy blood donors. The ethnic 
background of patients was caucasic, without HBV 
or HIV infection. Among HCV-positive patients, 230 
had a chronic HCV infection (CHC n = 230), 123 
patients had cirrhosis (CIR n = 123), 175 patients had 
hepatocellular carcinoma (HCC), and 334 patients 
had a lymphoproliferative disease including: 205 a 
cryoglobulinemic syndrome (MCS) defined according to 
previously described criteria [3] and 129 an overt B-cell 
non-Hodgkin’s lymphoma (NHL). Demographic and 
clinical characteristics of each groups were reported on 
Table 1. Patients had been recruited from: the MASVE 
Center, University of Florence, Azienda Ospedaliera 
Santa Maria degli Angeli, Pordenone, National Cancer 
Institute “Fondazione Pascale”, Naples, Departement of 
Biomedical Sciences and Human Oncology, University 
of Bari Medical School, Policlinico Universitario di 
Udine and Centro di Riferimento oncologico di Aviano, 
Italy. The diagnosis of chronic HCV infection was based 
on anti-HCV, elevated ALT serum levels and HCV RNA 
positivity of at least 6 months duration. An immunoassay 
test (III-generation EIA) against HCV-core and HCV-
non structural antigens were used. HCV genotype 
was determined by a commercial, certified, diagnostic 
test (Versant HCV Genotype 2.0, Siemens Healthcare 
Diagnostics, Deerfield, IL). Quantitative determination of 
HCV loads (RNA UI/mL) was done by branched DNA 
technology (Chiron, Emeryville, CA). The diagnosis 
of HCC was based on the standard criteria listed in the 
European Association for the Study of the Liver (EASL) 
that incorporate both invasive and noninvasive measures. 
Noninvasive criteria include two imaging techniques, 
both demonstrating a focal lesion > 2 cm in diameter with 
features of arterial hypervascularization. Detection and 
immunochemical characterization of cryoglobulins were 
performed according to consensus protocol proposed 
by A.L.CRI (Associazione Italiana per la Lotta alle 
Crioglobulinemie). NHL in the course of HCV infection 
has been histopathologically confirmed based on WHO 
classification [3]. The study was conformed to the ethical 
guidelines of the Helsinki Declaration and all subjects 
provided informed consent. Study was approved by 
independent local and independent ethics committees 
since this was a multicenter study.
Genetic polymorphisms of tlr2 and Il28b
Genomic DNA was extracted from whole 
blood using the EZ1 Qiagen blood kit and protocols 
recommended by the manufacturer (Qiagen Inc., 
Valencia, CA). Determination of TLR2 -196 to -174 ins/
del polymorphism was performed by Polymerase Chain 
Reaction (PCR) using the 5’-ctcggaggcagcgagaaa-3’ and 
5’-ctgggccgtgcaaagaag-3’ primers (10 pmol) in a reaction 
volume of 25 μl including 200 ng dNTPs and 0.5 U of 
GoTaq DNA Polymerase (Promega Corporation, Madison, 
WI). Cycling conditions were: initial denaturation at 95 
°C for 5 min, followed by 35 cycles at 95 °C for 30 sec, 
at 60°C for 40 sec and at 72 °C for 40 sec and then 72 
°C for 7 min. Fragments of different length (264 bp and 
286 bp), depending on the presence or absence of the 
deletion mutation were visualized by electrophoresis 
on a 3.5% agarose gel staining with ethidium bromide. 
IL28B genotyping was performed using a specific custom 
TaqMan SNP-genotyping Assay (SNP rs12979860; 
Applied Biosystem, Foster City, CA, USA) based on 
allele-specific dual-labelled probes on a 7900HT Fast 
Real-Time PCR system (Applied Biosystem, Foster City, 
CA, USA). Amplicon sequencing was used to validate the 
genotyping techniques. 
statistical analysis 
Specific tests including Fisher’s exact test and one 
or two-way analysis of variance were used to compare the 
patient groups regarding allele and genotype frequencies 
of TLR2 and IL28B polymorphisms, by direct counting 
of the positive individuals for a specific allele/genotype 
polymorphism. Multivariate logistic regression analysis 
was performed with diagnosis as a dependent variable 
and independent variables, including age, gender (0 
female; 1 male), and each genotype were also considered. 
P-value, odds ratio and 95% confidence interval were 
calculated. Genotypes of each polymorphism were 
Oncotarget37496www.impactjournals.com/oncotarget
assessed according to dominant (0 wild-type homozygote; 
1 heterozygote and variant homozygote), recessive 
(0 wild-type homozygote and heterozygote; 1 variant 
homozygote) and additive genetic models. Additive 
models comprised additive 1 (heterozygotes versus wild-
type homozygotes) and additive 2 (variant homozygotes 
versus wild-type homozygotes) models, which were 
analyzed simultaneously with a single statistical model. 
Statistical analyses were performed using GraphPad Prism 
v6. P value < 0.05 was considered significant. 
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